Table 1.
Characteristic | n (%) |
---|---|
Median age, years | 50 (21–83) |
< 40 years | 55 (18.2%) |
40–49 years | 92 (30.5%) |
50–59 years | 90 (29.8%) |
≥ 60 years | 65 (21.5%) |
Menopausal status | |
Premenopausal | 157 (52.0%) |
Postmenopausal | 145 (48.0%) |
Type of histology | |
Invasive ductal | 264 (87.4%) |
Invasive lobular | 18 (6.0%) |
Mixed | 11 (3.6%) |
Others | 9 (3.0%) |
Grade of histology | |
I | 13 (4.3%) |
II | 110 (36.4%) |
III | 152 (50.3%) |
Unknown | 27 (8.9%) |
Tumor size | |
I | 23 (7.6%) |
II | 145 (48.0%) |
III | 121 (40.1%) |
IV | 13 (4.3%) |
ER status | |
Positive | 218 (72.2%) |
Negative | 84 (27.8%) |
PgR status | |
Positive | 183 (60.6%) |
Negative | 119 (39.4%) |
HER2 status | |
Positive | 122 (40.4%) |
Negative | 180 (59.6%) |
Subgroups | |
HR+/HER2- | 151 (50.0%) |
HR+/HER2+ | 80 (26.5%) |
HR–/HER2+ | 42 (13.9%) |
TN | 29 (9.6%) |
Metastatic lymph nodes | 15 (10–53) |
10–15 | 159 (52.6%) |
» 16 | 143 (47.4%) |
Dissected lymph nodes | 23 (10–60) |
Lymph node ratio, median (range) | 0.75 (0.18–1.0) |
≤ 0.75 | 157 (52.0%) |
» 0.75 | 145 (48.0%) |
ER = estrogen receptor, PgR = progesterone receptor,
HER2 = human epithelial growth factor receptor 2,
HR = hormone receptor, TN = triple negative.